A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 05 Sep 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 05 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 29 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.